TVAX Biomedical, a biotech company focused on cancer cell vaccination and T cell cancer treatment, announced terms for its IPO on Monday. The Lenexa, KS-based company plans to raise $20 million by offering 2 million shares at a price range of $9.00 to $11.00. At the mid-point of the proposed range, TVAX Biomedical will command a market value of $81 million. TVAX Biomedical, which was founded in 2004, plans to list on the NASDAQ under the symbol TVAX. Roth Capital is the lead underwriter on the deal.
